{"name":"X4 Pharmaceuticals","slug":"x4-pharmaceuticals","ticker":"","exchange":"","domain":"x4-pharmaceuticals.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOazU5a2dyVWItMmcyVDRodzlFWU04YUhmMXpxVENMM3dBaEdmVU1TNmlfWm9rZFREenlId2R4ck42Q0pJaUZWbVJMdjNyM3RFY0hnMTU4eTg5ZnZCVENYOWFzLXhwUG1YVzA2UV9hNFZLcy1SWXI4S2ptTjAzLThXWXo1LWg2Zjk4U1gwNThINlVqaUNNci1mTHJJSHZPb0RkalJQTmFBWFpqRHUwbFpMVVhudnJaZw?oc=5","date":"2026-03-17","type":"regulatory","source":"Stock Titan","summary":"EMA panel backs first WHIM syndrome drug as X4 secures cash to 2028 - Stock Titan","headline":"EMA panel backs first WHIM syndrome drug as X4 secures cash to 2028","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQaVN3Y0VfM2dFOUlNRlAxWlEybkRsWFBLTE56VkFvWjhrdkdFMUdHOE5MWERndUZXRVJCSXlxSWdyWE9pZlRabHFoZWZqSXl4WlVLcjRJVXlkQWM1NUxnd0w3SFZZS1p6RXBTRXQ1YmtvV3RTZG9BZm5FWDdqamx4X1drekxEMnE4bGd4Slc2clZaT2xJN0VFMDJ4T2hnemRQbjNIaEVXTFh2dERqbmV3N1dqdmNSa1dpV25jenBHR3FRdHRTNWJGSmJtQQ?oc=5","date":"2026-03-09","type":"pipeline","source":"24/7 Wall St.","summary":"X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - 24/7 Wall St.","headline":"X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbWdoWEFOSG1XaWtrMTZsVVBrYTFVQjRLQTJoQkNOMFc0Q3Nac0hLb1RQZ2l4Y1c5TXFpNUJ3dkdfbzgxeGQxTzBHTkJYVGMwYnhMeU5fNDgyT1E0amxiZ08wWFFSUzlsbTJTQW1PR3J3WWpQT0tmbmlOeXpLaWZnc3NUUDJocUNHdWpKZlVPaWhBMGlUSWZsMUVoRVVJdDZnaDlYMFR6cmdqUQ?oc=5","date":"2025-12-01","type":"pipeline","source":"Seeking Alpha","summary":"X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha","headline":"X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQSzloQzdCbDB2X1pZc0RWWjFUcFI2Zkp1RjlYSktJOEFEZHFhSVoxMWp2elljRFpMN0hoYXNEUzZrNHlldTloZU9lWUpMNExOVmNDb0xRVTg0SFNyd0tJMTVma3JnVnI4UzZXa0hORFJKd2N5ZG5yajVleHVSZ1Ryd293c1pKSmhFTl9mOUE1SlVlRHljd1NkZlpZWHd0RjYwTXV3Z01DTkhzVVRYb3NVOUx4dlFrSVN5OEdUUUdhU3NTelBV?oc=5","date":"2025-10-24","type":"pipeline","source":"TradingView","summary":"X4 Pharma rallies nearly 50% after $135 mln share offering - TradingView","headline":"X4 Pharma rallies nearly 50% after $135 mln share offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQeDNTMTdhLUZlZFdRRGlLRi0tenVraWVfQnNaQnhxMFRxVHpKTzRFTkdOQVpaZXV1eFdJRmh3NUEyb1dqMS1WbkxXdEdpaVJHLTVfVkRQRUpka2dyWGIyTWVYbHI2ZGRjR1VyNzdLaFlfbU1vcXhmT3JsVlk2TGZzOTZYVWJISmNLT1d5YUplUjdWMjZNbE5Zbl9SSmtwbTVRa1ZxS2tuVS1faUVqUkZBbWxoNzZKVk5JUXk0?oc=5","date":"2025-09-17","type":"trial","source":"Fierce Pharma","summary":"Cost-cutting X4 chops head count by 50%, lays off execs in mission to complete Xolremdi expansion study - Fierce Pharma","headline":"Cost-cutting X4 chops head count by 50%, lays off execs in mission to complete Xolremdi expansion study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBtRUNDMDVWX29xbWUwdkpQbUhMMjhTUjcxNl9PU2piY1JCWVhKc3JUNWRFcmxWZExDV3doVE9BY1hBSlZBcC02cDNCS3lkMklHWkxR?oc=5","date":"2025-09-17","type":"pipeline","source":"FirstWord Pharma","summary":"X4 Pharma halves workforce in second round of layoffs this year - FirstWord Pharma","headline":"X4 Pharma halves workforce in second round of layoffs this year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOOF9FS25VNUVWTWNjSVFPWW40a1lOMTZENlJ0SFlBX01zZUpLQW9lYW9BeTN3Y08yV2dtc09GZDZ6Z0tjbDg5RE93d1lHUHliaUhqbTR4WUxic09HdFlRUjNVaWJwSXQzRUl3a3lvMUFvRG5UQlZmLThKWF8zR040Tw?oc=5","date":"2025-08-13","type":"pipeline","source":"StocksToTrade","summary":"Is X4 Pharmaceuticals Nearing a Breakthrough? - StocksToTrade","headline":"Is X4 Pharmaceuticals Nearing a Breakthrough?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQU3dfRnBTZHlrMEd5TTBhZjNwUzZOQ0NWTEVfOW16OTZ5Y09FUmZPRkd5WnI1bUg5MjdRdEN0VTQ5cDFjYjdLYTNibURSRFRUMnhXT0kxb0doUDFQd2RhR3d2YWh0Y1k5X0hxYXdzS3F4LWtMUWJneGlJU0ZCRk5rNGctdHZEQ2hJeXV5ZVF3?oc=5","date":"2025-08-12","type":"pipeline","source":"Yahoo Finance","summary":"X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership - Yahoo Finance","headline":"X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNOGFBdHJ1ZENWdzlLemlqMF9udlhfaTN1WUVnUWZibFA4a0NoczJkeS1nVWIteDQtX1daMF9KeGR0ckxoMl9hTXJYazY4LWxqZWxNbl9pYlJNMkFxNmFtX25BVEVtU2J6eE1SRWJldWpBNjZUalpaXzV2T1Y1SUNWYW9qWDA1RGZVeFFpN1hyMHp3YS1HX3lGMFVlMjY?oc=5","date":"2025-02-06","type":"pipeline","source":"BioSpace","summary":"X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce - BioSpace","headline":"X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNdEFCcHdZbkQtaTlBUUhrRkh3U2NxNFdKTEFLUmZ3SWZOWDRWdm9IQUJBandMdVl0TDdMUEFwc1AtaTBYdmZ5b2FrR3pJZ0FnYXVuUGxLaDlydzRxOUY1QTVPQkk1cXQ1V2p2SDZiYnlZVGVFVzJDT2daWnBUZlZxRmhwRTE2RGZ3eFZ0cEp3R1JrUG5XVHU5dzlEVEMwcVE?oc=5","date":"2025-02-06","type":"pipeline","source":"Fierce Biotech","summary":"X4 lays off 30% of staff, halts preclinical R&D to focus on Xolremdi rollout - Fierce Biotech","headline":"X4 lays off 30% of staff, halts preclinical R&D to focus on Xolremdi rollout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxPbndRcXU4TV9YZnB5cXpaam1WYmJ5MkNNYVdGT0JpQzZVNlM5bFJ6WTRVR3RUeFVqdTF6aFR0T0steG55MkZJbWFlZlI4aEZ1alNLdGM5ZVppTnlVa0lzd245QnBsNU93Y2M4OXFRdnN3eTJ6cW5ETHA0Z3VCLUgtLUhxcEtLeTc0Wl9RRy1ULWRjdkktc3JOUk4zUlRBd2h1NFJvaHJRd0d6S3ROcF9ZR2Itc0dQX2FZcFFkc29abG0tQ0ZMVUxSTTV5WEQ5S1VfVXZHOGFjQzFIaGZhSmE3bnlBQ3dhaDRLTThGX3J2WXhmYXJnWF9ETkNtQ294MmszdnFSX1ZwSjMxS082a3U0SVJYRkxCMklySS1iXzFiLVExam9mTF9weVFDZHZkSEsxN1hGdUh4cw?oc=5","date":"2025-01-24","type":"regulatory","source":"PR Newswire","summary":"X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe. - PR Newswire","headline":"X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to N","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE51R2tXc2U3ajRWc2JmR3IwQmNkUnNJckFrS3B3UXlwLWdvMFZLTkFEc3lIRlNjc0Z1VnJsQVVwLXdmRXE0YTRROFJVNnJrYWNvaF93TlJYclBXcXdubEFZaTZTME5ZbXF6azRwVlM1V3BRZw?oc=5","date":"2024-07-13","type":"pipeline","source":"The Pharma Letter","summary":"X4 Pharmaceuticals | Biotechnology | The Pharmaletter - The Pharma Letter","headline":"X4 Pharmaceuticals | Biotechnology | The Pharmaletter","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}